You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
江蘇吳中(600200.SH)連續兩日漲停 阿比多爾僅嘗試治療新冠病毒
格隆匯 02-03 19:08

格隆匯2月3日丨江蘇吳中(600200.SH)公佈,公司股票於2020年1月23日、2月3日連續兩個交易日內收盤價格漲幅偏離值累計超過20%,根據《上海證券交易所交易規則》的有關規定,屬於股票交易異常波動的情形。

截至2020年2月3日收盤,公司動態市盈率為78.35倍,動態市盈率較高。公司2019扣除非經常性損益後預計虧損8000萬元左右。

鹽酸阿比多爾片為吳中醫藥在產在銷產品之一。目前阿比多爾僅被嘗試性用於治療“新型冠狀病毒”,尚無充足的臨牀研究證據表明該產品對“新型冠狀病毒”有療效。

2019年1-9月,吳中醫藥鹽酸阿比多爾片銷售收入為1602.8萬元,占上市公司營業收入1.06%;2018年同期銷售收入為583.9萬元,占上市公司營業收入0.42%。該藥品銷售收入占上市公司營業收入比例極小。

截至目前,吳中醫藥就本次疫情分批向武漢協和醫院及蘇州紅十字會捐贈的藥品價值合計100多萬元。捐贈的藥品以抗病毒、增強免疫力藥品為主,包括鹽酸阿比多爾片、匹多莫德口服溶液以及利巴韋林注射液。上述捐贈事宜不會對公司當期及未來經營業績構成重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account